ARTICLE | Clinical News

rHb1 data

October 31, 1994 8:00 AM UTC

The Boulder, Colo., company said it completed a Phase I/II study in 14 surgical patients at doses of up to 25.6 g. The company didn't say how many patients in this trial received that highest dose, but it did say that a total of 5 or 6 people in an earlier study and in this trial received a high dose ranging from 20-26 g. The high dose varies because it's based on patient weight.

No major adverse events, including kidney or pulmonary toxicities, were reported. Nor was there any of the gastrointestinal discomfort experienced by normal volunteers in an earlier study, SMTG said. Patients received no prophylaxis to prevent GI discomfort. ...